GlobeNewswire
Sale of assets related to Flow Cytometry & Imaging (FCI) Business UnitAcquisition will expand Cytek’s product portfolio to include imaging and menu-based application driven flow cytometry to provide full cell analysis solutions to its customersTransaction is in line with DiaSorin’s strategic priorities communicated to the market after Luminex acquisitionEmployees associated with commercial, operations, R&D and supporting functions expected to join Cytek SALUGGIA, Italy and FREMONT, Calif., Feb.